Sector News

Glaxo pharma chief Hussain joins sea of departing execs

January 20, 2017
Life sciences

The leadership changes just keep on coming at GlaxoSmithKline. The latest? Global pharma president Abbas Hussain is out, and AstraZeneca vet Luke Miels is in.

Hussain has decided to leave the company and will make his exit later this year, GSK said Thursday without specifying a date. When he does, Miels, currently EVP of AstraZeneca’s European business, will step in.

The move will mark the end of eight-plus years at GSK for Hussain, whom the company credits with building the world’s No. 1 pharma business by volume and implementing its new, quota-free sales model across 100 countries.

Hussain is hardly the only long-tenured GSK exec headed for the door. Since CEO Andrew Witty announced last year that he would be turning over the reins this March, both vaccines chairman Moncef Slaoui and ViiV head Dominique Limet have decided to bid the company farewell.

“Succession processes are challenging for everyone involved and, unfortunately, it is rare that all of those involved stay with the company,” Witty said in a statement.

GSK, though, is hoping for big things from Miels, who launched cancer-fighter Tagrisso and jump-started growth of key heart med Brilinta at AstraZeneca. Glaxo will need his commercial smarts to keep the ball rolling on its own new launches, which have slowly but surely grown enough to start filling the gap left by waning giant Advair—especially with incoming CEO Emma Walmsley, whose own background lies in consumer health, at the helm.

“We are now entering a critical period of commercialization for our new pharmaceutical products and, over the next two to three years, we have important data to come on our early-stage pipeline,” Walmsley said in a statement. “Luke will bring a strong new voice to the decisions and choices we will have to make.”

And as the British pharma giant’s chief strategy officer, David Redfern, figures, those decisions will be many. Walmsley is “taking the time during the transition to really understand the business, and obviously she’s spending most of her time on the pharma side, … particularly R&D,” he told FiercePharma in an interview during the J.P. Morgan Healthcare Conference.

But “we have a lot of science” outside of the company’s anchor respiratory and HIV businesses—including cardiovascular and gene therapy programs, he noted—“so what choices we make and when over the next few years is a big question.”

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).